翻译资源

获得广泛生存的NSCLC靶向药物
The target drug providing an extended survival in NSCLC.

华译网上海翻译公司曾经翻译过大量有关药代动力学的资料文件，Beijing Chinese Subtitling Translation Service Agency has translated many technical documents about Pharmacokinetic.
掌握生存的力量 
Power to prolong Survival
特罗凯（Tarceva）?被证实对晚期NSCLC患者具有生存优势的HER1/EGFR酪氨酸激酶抑制剂
It is proved that Tarceva? is a HER1/EGFR tyrosine kinase inhibitor that shows survival advantage in patients with advanced NSCLC.
特罗凯?对腺癌和鳞癌患者均提供临床获益1，2
Tarceva? provided clinical benefit in both patients with adenocarcinoma and those with squamous cell carcinoma.
生存率
Survival rate
随访月数
Follow-up months
Log-rank分析
Log-rank analysis
特罗凯?使吸烟的鳞状细胞癌男性患者获得生存益处1，2
Tarceva? showed survival benefit in the male smoking patients with squamous cell carcinoma.
生存率
Survival rate
特罗凯?（n=100） 中位生存期5.5个月
Tarceva?（n=100）Median survival: 5.5 months
安慰剂（n=57） 中位生存期3.4个月
Placebo (n=57) median survival: 3.4 months
HR = 0.66 （95% CI 0.47-0.92） p = 0.016
HR = 0.66 （95% CI  0.47-0.92） p = 0.016
随访月数
Follow-up months
对所有NSCLC患者人群都有生存优势的靶向药物
The target drug providing survival advantage in all NSCLC patient groups.
特罗凯（Tarceva）?被证实对晚期NSCLC患者具有生存优势的HER1/EGFR酪氨酸激酶抑制剂
It is proved that Tarceva? is a HER1/EGFR tyrosine kinase inhibitor that shows survival advantage in patients with advanced NSCLC.
特罗凯?每天150mg保证高血浆药物暴露
Tarceva? 150mg per day guaranteed high level of systemic drug exposure.
特罗凯?剂量与Cmax和AUC成正相关，特罗凯?每天一次重复给药不会导致药物蓄积
The dose of Tarceva? was positively correlated with Cmax and AUC. Daily dosing of Tarceva? repeatedly didn’t result in drug accumulation.
药代动力学证据提示使用推荐剂量特罗凯?的血浆药物暴露要远高于吉非替尼的血浆药物暴露
The pharmacokinetic evidence indicated that drug exposure of taking recommended dose of Tarceva? was significantly higher than that of Gefitinib.
BR.21证实特罗凯??对难治的NSCLC患者疗效卓越
BR.21 proved that Tarceva? provided significant beneficial effect in patients with refractory NSCLC.
全面提高患者生活质量，服用方便，耐受性理想
Broadly improvement of patients’ life of quality  Taken conveniently  Ideal tolerance
生存获益明确  生存质量更佳
Definite survival benefit  Better quality of life
掌握生存的力量 
Power to Prolong Survival
医生对目前治疗方案的期望
Physician’s expectation of current therapy regimen:
提高患者生存期，延长疾病进展时间
To increase survival of patients  To prolong time to progress time
显著缓解疾病症状，改善生活质量
To relieve symptoms of disease remarkably  To improve quality of life.
适合全身状况差的患者，耐受性优异
To suit for patients with badly performance status  Excellent tolerance
化疗失败后患者亦可使用
Can be used in patients who failed prior chemotherapy
特罗凯?延长症状恶化时间，改善患者生活质量1，2，3，4
Tarceva? prolonged time to symptom deterioration and improved patients’ quality of life1，2，3，4
全面提高患者生活质量 服用方便 耐受性理想
Broadly improvement of patients’ life of quality  Taken conveniently  Ideal tolerance
特罗凯?被证实对晚期NSCLC患者具有生存优势的HER1/EGFR酪氨酸激酶抑制剂
It is proved that Tarceva? is a HER1/EGFR tyrosine kinase inhibitor that shows survival advantage in patients with advanced NSCLC.
特罗凯?显著延长非小细胞肺癌患者生存3
Tarceva? significantly prolonged survival in patients with NSCLC3
特罗凯? （N=488） 对照组（N = 243）
Tarceva? (N=488)  Control group (N = 243)
生存率
Survival rate
中位生存期 ↑42.5% （6.7个月vs. 4.7个月）
Median survival ↑42.5% （6.7 months vs. 4.7 months）
HR 0.70 死亡风险 ↓30% （95% CI = 0.58-0.85；P<0.001）
HR 0.70  Death risk ↓30% （95% CI = 0.58-0.85；P<0.001）
一年生存率：↑45% （31.2% vs. 21.5%）
One-year survival rate:↑45% （31.2% vs. 21.5%）